JP2008534522A - 医薬組成物のための複合ステップ製造方法 - Google Patents

医薬組成物のための複合ステップ製造方法 Download PDF

Info

Publication number
JP2008534522A
JP2008534522A JP2008503332A JP2008503332A JP2008534522A JP 2008534522 A JP2008534522 A JP 2008534522A JP 2008503332 A JP2008503332 A JP 2008503332A JP 2008503332 A JP2008503332 A JP 2008503332A JP 2008534522 A JP2008534522 A JP 2008534522A
Authority
JP
Japan
Prior art keywords
disorders
levetiracetam
pharmaceutical
tablets
bed drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008503332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534522A5 (enExample
Inventor
デヴィッド エー． キャロン
リナ アル−バルガシュ
Original Assignee
ジェンファーム インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェンファーム インク filed Critical ジェンファーム インク
Publication of JP2008534522A publication Critical patent/JP2008534522A/ja
Publication of JP2008534522A5 publication Critical patent/JP2008534522A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008503332A 2005-03-30 2006-03-30 医薬組成物のための複合ステップ製造方法 Pending JP2008534522A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2505463 2005-03-30
PCT/CA2006/000470 WO2006102750A1 (en) 2005-03-30 2006-03-30 Combined-step process for pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2008534522A true JP2008534522A (ja) 2008-08-28
JP2008534522A5 JP2008534522A5 (enExample) 2009-04-02

Family

ID=37052908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503332A Pending JP2008534522A (ja) 2005-03-30 2006-03-30 医薬組成物のための複合ステップ製造方法

Country Status (5)

Country Link
US (1) US8216611B2 (enExample)
EP (1) EP1871363A4 (enExample)
JP (1) JP2008534522A (enExample)
AU (1) AU2006228947A1 (enExample)
WO (1) WO2006102750A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017206467A (ja) * 2016-05-19 2017-11-24 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP2020180101A (ja) * 2019-04-26 2020-11-05 東和薬品株式会社 レベチラセタム含有医薬組成物の製造方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
FR2912056B1 (fr) * 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
ATE542525T1 (de) * 2007-10-16 2012-02-15 Pharmathen Sa Verbesserte pharmazeutische zusammensetzung mit einem pyrrolidon-antikonvulsivum und verfahren zu seiner herstellung
JP2010024156A (ja) * 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
ES2865504T3 (es) * 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
EP2179725A1 (en) * 2008-10-23 2010-04-28 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising levetiracetam
EA037187B1 (ru) * 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
HK1216513A1 (zh) 2013-03-15 2016-11-18 阿普雷奇亚制药有限责任公司 包含左乙拉西坦的快速分散劑型
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN115350178B (zh) * 2022-08-24 2024-04-26 浙江京新药业股份有限公司 一种包含左乙拉西坦的药物组合物
CN119679738B (zh) * 2025-02-27 2025-06-20 福安药业集团宁波天衡制药有限公司 一种巴氯芬片及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1029931A (ja) * 1996-04-03 1998-02-03 Basf Ag 吸湿性、水溶性製品顆粒
JPH11319534A (ja) * 1998-03-18 1999-11-24 Hosokawa Micron Corp 造粒装置
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
JP2001224327A (ja) * 2000-02-15 2001-08-21 Ogawa & Co Ltd 粉末酸味料及びその製造方法
JP2003508441A (ja) * 1999-08-31 2003-03-04 シェーリング アクティエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
WO2003101428A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische zusammensetzung mit verzögerter wirkstofffreisetzung, verfahren zu derer zubereitung
WO2004037293A1 (ja) * 2002-10-22 2004-05-06 Dainippon Pharmaceutical Co., Ltd. 安定化組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US5204115A (en) * 1990-12-12 1993-04-20 Suomen Xyrofin Oy Directly compressible xylitol and method
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
YU37602A (sh) 1999-12-01 2005-07-19 Ucb S.A. Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
EP1118321A1 (fr) * 2000-01-14 2001-07-25 Ucb, S.A. Compositions pharmaceutiques solides pour la libération contrôlée de substances actives
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
EP1517893A2 (en) 2003-02-03 2005-03-30 Teva Pharmaceutical Industries Limited Process for producing levetiracetam
CA2525366A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
NZ556630A (en) 2005-01-27 2010-12-24 Alembic Ltd Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
US8431156B2 (en) 2005-02-22 2013-04-30 Sun Pharma Advanced Research Company Ltd. Pharmaceutical composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1029931A (ja) * 1996-04-03 1998-02-03 Basf Ag 吸湿性、水溶性製品顆粒
JPH11319534A (ja) * 1998-03-18 1999-11-24 Hosokawa Micron Corp 造粒装置
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
JP2003508441A (ja) * 1999-08-31 2003-03-04 シェーリング アクティエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
JP2001224327A (ja) * 2000-02-15 2001-08-21 Ogawa & Co Ltd 粉末酸味料及びその製造方法
WO2003101428A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische zusammensetzung mit verzögerter wirkstofffreisetzung, verfahren zu derer zubereitung
WO2004037293A1 (ja) * 2002-10-22 2004-05-06 Dainippon Pharmaceutical Co., Ltd. 安定化組成物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017206467A (ja) * 2016-05-19 2017-11-24 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP2020180101A (ja) * 2019-04-26 2020-11-05 東和薬品株式会社 レベチラセタム含有医薬組成物の製造方法
JP7264711B2 (ja) 2019-04-26 2023-04-25 東和薬品株式会社 レベチラセタム含有医薬組成物の製造方法

Also Published As

Publication number Publication date
AU2006228947A1 (en) 2006-10-05
US20090074854A1 (en) 2009-03-19
US8216611B2 (en) 2012-07-10
EP1871363A4 (en) 2009-01-21
EP1871363A1 (en) 2008-01-02
WO2006102750A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
JP3563036B2 (ja) セレコキシブ組成物
JP5714492B2 (ja) 粒状体、それらの調製方法、およびそれらを含む医薬品
JP3589977B2 (ja) 活性成分としてクロドロン酸塩および賦形剤としてケイ化微晶質セルロースを含む医薬製剤
JP2008534522A (ja) 医薬組成物のための複合ステップ製造方法
TWI228414B (en) Pharmaceutical composition comprising carvedilol and hydrochlorothiazide, solid dosage form comprising it, and process for the production of the same
US10449185B2 (en) Formulations of pimavanserin
JPH0753361A (ja) 放出が調整された調合物、経口投与形態及びその製造方法
JPH01503070A (ja) 薬剤持続放出マトリツクス及び方法
CN103402497A (zh) 快速分散颗粒、口腔崩解片以及方法
HK87893A (en) Orally sustained-release acetaminophen formulation and process to obtain it
WO2007074856A1 (ja) 口腔内崩壊性固形製剤の製造法
JP2002543137A (ja) アセチルサリチル酸およびクロピドグレル硫酸水素塩を含む単位形態における医薬組成物
JP2013534242A (ja) ナルブフィンを含有する製剤及びそれらの使用
CN104379147A (zh) 制备用于口服给药的低剂量恩替卡韦制剂的方法
JP2012051810A (ja) 口腔内崩壊錠およびその製造法
CN105073101B (zh) 具有高含量非索非那定的固体单元及其制备方法
JP3341768B1 (ja) 分岐鎖アミノ酸を含有するチュアブル剤
CN105407875A (zh) 包含异烟肼颗粒和利福喷汀颗粒的呈包衣片剂形式的抗结核病的稳定的药物组合物及其制备方法
JP4756153B2 (ja) 低成分含量の錠剤の製造方法
AU2012201676B2 (en) Combined-step process for pharmaceutical compositions
JP2000516601A (ja) 水溶性化合物及びセルロースを含有する粒状物
CA2603316C (en) Combined-step process for pharmaceutical compositions
WO2012107092A1 (en) Pharmaceutical composition comprising tadalafil and a cyclodextrin
JP2842244B2 (ja) イデベノン粒剤およびその製造法
CN112022827B (zh) 一种盐酸赛庚啶快速释放药物制剂及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120514

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120911